Alzinova AB (publ) (ticker: ALZ) is pleased to announce the release of the drug substance for its upcoming Phase 2 clinical trial of the vaccine candidate ALZ-101 in early Alzheimer's disease. This mi ...

Proteins form the structural and functional backbone of the cell, and any perturbation in their synthesis can disrupt normal ...

Spring beauty trends are in full force on LTK. Chief among those dominating the creator commerce app, which generates $5 ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

Viking's Q1 earnings show no revenue, increased R&D spending, and a substantial cash reserve, positioning it well for future ...

Jaime Almandoz, MD, MBA, of UT Southwestern Medical Center, speaks on results of a study that investigated tirzepatide uptake ...

Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

Increased awareness and knowledge of GLP-1/GIP receptor agonists among women, with insights into public perspectives on ...

The future of treating metabolic dysfunction–associated steatohepatitis (MASH) looks brighter than ever, says Naim Alkhouri, MD, as data emerges on newly developed interventions.

Quantumzyme Corp. (OTC: QTZM), a biotechnology company leveraging computational enzyme engineering, is pleased to announce the upcoming publication of its patent for an innovative enzymatic method to ...

New research being presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) shows that ...

Kelly-Ann Franklin has spent more than two decades in journalism which has helped her build a wide knowledge base of business and personal finance topics. Her goal with editing is to ensure tough ...